

# Mohsen Beheshti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9056984/publications.pdf>

Version: 2024-02-01

62  
papers

2,784  
citations

279798

23  
h-index

175258

52  
g-index

67  
all docs

67  
docs citations

67  
times ranked

2802  
citing authors

#	ARTICLE	IF	CITATIONS
1	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	6.4	589
2	Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1766-1774.	6.4	270
3	<sup>18</sup> F Choline PET/CT in the Preoperative Staging of Prostate Cancer in Patients with Intermediate or High Risk of Extracapsular Disease: A Prospective Study of 130 Patients. Radiology, 2010, 254, 925-933.	7.3	269
4	The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Molecular Imaging and Biology, 2009, 11, 446-454.	2.6	143
5	The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. European Radiology, 2009, 19, 1425-1434.	4.5	120
6	Impact of <sup>18</sup> F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics. Journal of Nuclear Medicine, 2013, 54, 833-840.	5.0	111
7	Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1486-1499.	6.4	107
8	Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases. Seminars in Nuclear Medicine, 2009, 39, 396-407.	4.6	106
9	18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 491-501.	4.6	98
10	The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT. Molecular Imaging and Biology, 2010, 12, 98-107.	2.6	97
11	Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography—a novel concept. Hellenic Journal of Nuclear Medicine, 2011, 14, 114-20.	0.3	85
12	HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1371-1389.	6.4	63
13	Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 824-831.	6.4	51
14	Evaluation of Prostate Cancer Bone Metastases with <sup>18</sup> F-NaF and <sup>18</sup> F-Fluorocholine PET/CT. Journal of Nuclear Medicine, 2016, 57, 55S-60S.	5.0	47
15	Radiomics Analysis for Clinical Decision Support in Nuclear Medicine. Seminars in Nuclear Medicine, 2019, 49, 438-449.	4.6	38
16	Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 96-108.	1.0	36
17	Multiphasic <sup>68</sup> Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients. Journal of Nuclear Medicine, 2020, 61, 1484-1490.	5.0	34
18	[18F]FDG-PET/CT Radiomics and Artificial Intelligence in Lung Cancer: Technical Aspects and Potential Clinical Applications. Seminars in Nuclear Medicine, 2022, 52, 759-780.	4.6	33

#	ARTICLE	IF	CITATIONS
19	[18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1316-1317.	6.4	32
20	Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1188-1196.	6.4	32
21	The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors. <i>Current Cancer Drug Targets</i> , 2005, 5, 139-148.	1.6	30
22	Therapy assessment of bone metastatic disease in the era of 223radium. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 84-96.	6.4	30
23	Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients. <i>Nuclear Medicine Communications</i> , 2015, 36, 1065-1075.	1.1	25
24	Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2130.	2.4	24
25	Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4028-4041.	6.4	24
26	Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. <i>Journal of Clinical Medicine</i> , 2020, 9, 2622.	2.4	22
27	BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study). <i>Molecular Imaging and Biology</i> , 2015, 17, 424-433.	2.6	21
28	2-[18F]FDG PET/CT radiomics in lung cancer: An overview of the technical aspect and its emerging role in management of the disease. <i>Methods</i> , 2021, 188, 84-97.	3.8	21
29	18F-Sodium Fluoride PET/CT and PET/MR Imaging of Bone and Joint Disorders. <i>PET Clinics</i> , 2018, 13, 477-490.	3.0	20
30	Fluorocholine PET/Computed Tomography. <i>PET Clinics</i> , 2014, 9, 299-306.	3.0	16
31	Incremental Impact of [68Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. <i>Molecular Imaging and Biology</i> , 2022, 24, 50-59.	2.6	16
32	Detection of bone metastases in patients with prostate cancer by F-18 fluorocholine and F-18 fluoride PET/CT: a comparative study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1766.	6.4	15
33	Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target. <i>Cells</i> , 2020, 9, 2334.	4.1	14
34	Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. <i>Cancers</i> , 2021, 13, 5360.	3.7	13
35	PET Imaging of Prostate Cancer Using Radiolabeled Choline. <i>PET Clinics</i> , 2009, 4, 173-184.	3.0	12
36	Artificial intelligence and radiomics in pediatric molecular imaging. <i>Methods</i> , 2021, 188, 37-43.	3.8	12

#	ARTICLE	IF	CITATIONS
37	ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	11
38	Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 910-911.	6.4	10
39	Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2308.	2.4	9
40	Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2715.	2.4	9
41	Prostate-specific membrane antigen radioligand therapy of prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 29-36.	0.7	8
42	Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. <i>European Journal of Radiology</i> , 2022, 146, 110107.	2.6	8
43	18F NaF PET/CT in the Assessment of Metastatic Bone Disease. <i>PET Clinics</i> , 2012, 7, 303-314.	3.0	6
44	Molecular imaging of bone metastases using tumor-targeted tracers. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 136-149.	0.7	6
45	PET Tracers Beyond FDG: Normal Variations and Benign Findings. <i>PET Clinics</i> , 2014, 9, xi-xii.	3.0	5
46	Hepatic candidiasis mimicking lymphoma on 18F-FDG PET/CT in a patient with T cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2925-2926.	6.4	4
47	Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 80-80.	1.6	4
48	18F Choline PET/CT in a patient with HRPT2 mutation: Detecting parathyroid carcinoma recurrence and concomitant breast carcinoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, , .	0.7	4
49	68Ga-PSMA PET/CT with MRI fusion: spinal cord metastasis from prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 348-349.	6.4	3
50	Feasibility of equivalent performance of 3D TOF [18F]-FDG PET/CT with reduced acquisition time using clinical and semiquantitative parameters. <i>EJNMMI Research</i> , 2021, 11, 44.	2.5	3
51	Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 563-568.	6.4	2
52	Quantitative in vivo assessment of bone allograft viability using 18F-fluoride PET/CT after glenoid augmentation in reverse shoulder arthroplasty: a pilot study. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2019, 29, 1399-1404.	1.4	2
53	PET/CT and PET/MRI, Normal Variations, and Artifacts. , 2020, , 549-584.		2
54	PET/MRI as a research tool in musculoskeletal conditions. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , .	0.7	2

#	ARTICLE	IF	CITATIONS
55	FDG PET/CT: Normal Variations and Benign Findings - Translation to PET/MRI. PET Clinics, 2014, 9, xiii-xiv.	3.0	1
56	Nuclear Medicine Modalities to Image Bone Metastases with Bone-Targeting Agents: Conventional Scintigraphy and Positron-Emission Tomography. , 2017, , 61-74.		1
57	Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor. EXCLI Journal, 2019, 18, 273-276.	0.7	1
58	Gastroenteropancreatic Neuroendocrine Neoplasms. , 2018, , 85-109.		0
59	Accurate detection of intracranial extension of jugulotympanic paraganglioma by [18F]FDOPA-PET/CT comparing to MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 412-414.	6.4	0
60	Prostate Cancer: Role of Conventional Radionuclide and Hybrid Bone Imaging. , 2012, , 635-659.		0
61	Imaging of Metastatic Bone and Soft Tissue Lesions in Prostate Cancer with FCH PET/CT. , 2013, , 222-225.		0
62	Nuklearmedizin der Prostata und des Männlichen Genitale. , 2016, , 1265-1275.		0